首页> 外国专利> Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c

Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c

机译:高基线HbA1c患者的糖尿病及相关疾病的治疗方法

摘要

The present invention is directed to treatments for a disease or condition, in a subject in need thereof, that provide alternatives to treatment by injection that give, relative to treatment by injection, improved treatment outcomes, 100% treatment compliance, reduced side effects, and rapid establishment and/or termination of substantial steady-state drug delivery. The method includes providing continuous delivery of a drug from an implanted osmotic delivery device, wherein substantial steady-state delivery of the drug at therapeutic concentrations is achieved within about 7 days after implantation of the osmotic delivery device in the subject and the substantial steady-state delivery of the drug from the osmotic delivery device is continuous over a period of at least about 3 months. In one embodiment, the present invention is directed to treatment of type 2 diabetes mellitus using insulinotrophic peptides. In embodiments, a subject has a baseline HbA1c % of greater than 6.5% or 10.0%.
机译:本发明针对有需要的受试者中的疾病或病症的治疗,其提供了注射治疗的替代方案,相对于注射治疗,该替代方案提供了改善的治疗结果,100%的治疗依从性,减少的副作用以及快速建立和/或终止大量稳态药物输送。该方法包括从植入的渗透递送装置提供药物的连续递送,其中在将渗透递送装置植入受试者体内后约7天内达到治疗浓度的药物的基本稳态递送和基本稳态从渗透递送装置递送药物的过程持续至少约3个月。在一个实施方案中,本发明涉及使用胰岛素营养肽治疗2型糖尿病。在实施方案中,受试者的基线HbA1c%大于6.5%或10.0%。

著录项

  • 公开/公告号US10583080B2

    专利类型

  • 公开/公告日2020-03-10

    原文格式PDF

  • 申请/专利权人 INTARCIA THERAPEUTICS INC.;

    申请/专利号US201815868708

  • 发明设计人 THOMAS R. ALESSI;MICHELLE BARON;

    申请日2018-01-11

  • 分类号A61K38/26;A61K9;A61K38/17;A61K45/06;G01N33/72;

  • 国家 US

  • 入库时间 2022-08-21 11:26:13

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号